Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 aztreonam inhalation trial for early Pseudomonas eradication in pediatric cystic fibrosis
NL-OMON37937Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Apr 2012
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aztreonam in Pseudomonas aeruginosa airway infection and cystic fibrosis (CF), sponsored by Gilead Sciences. Primary endpoints: Sustained Pseudomonas aeruginosa eradication through 6 months and Pseudomonas aeruginosa-specific antibody titers at Day 196. Started Apr 2012; status: active, not recruiting.
02
Drugs
aztreonam
03
Conditions
Pseudomonas aeruginosa airway infectioncystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON37937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37937.